The MLL gene is frequently rearranged in leukemias, and MLL chimeric proteins generated by chromosomal translocations play crucial roles in leukemogenesis. Targets 
Introduction
The mixed lineage leukemia (MLL) gene (also known as ALL-1, HRX, and HTRX) located at the chromosome band 11q23 is frequently rearranged by reciprocal chromosomal translocations especially in infantile and therapy-related leukemias. [1] [2] [3] [4] [5] [6] [7] Such translocations result in the expression of chimeric transcripts that are fused in frame between the MLL gene and various partner genes. The MLL gene encodes a 431-kDa protein, which comprises 3,969 amino acids. 3, 4 In the N-terminus region MLL protein contains three A-T hook motifs that can bind DNA, and a DNA methyltransferase homology domain that possibly regulates the transcription of its target genes. 8 Recent study demonstrated that the A-T hook of MLL binds the promoter region of the ARP-1 gene, that is down-regulated in the Mll−/− ES cells. 9 In the central and C-terminus portions MLL has three PHD-type zinc-finger domains and a domain for the protein interaction known as SET. 3, 4 These domains share a significant homology to Drosophila Trithorax protein that positively regulates the expression of the homeobox genes. 3, 4 The SET domain of MLL interacts with hSNF5/INI1, a component of the SNF/SWI complex, a chromatin remodeling system. 10 The SET domain is lost when amino-terminal MLL fuses to partner proteins in leukemic cells. Therefore, MLL fusion proteins lack MLL functions mediated by this domain.
Over 20 different translocation partners of the MLL gene have been identified to date. 5, 6 The most common fusion part- ners are AF4 in t(4;11)(q21;q23), AF9 in t(9;11)(p22;q23), and ENL in t(11;19)(q23;p13). 5, 6 AF4, AF9, and ENL are putative transcription factors and these proteins activate transcription from synthetic reporter genes. [11] [12] [13] Knock-in mice expressing Mll-AF9 under the natural Mll promoter developed leukemia, while the knock-in of the N-terminal truncated MLL fused to a MYC-tag did not induce leukemia. 14 These findings suggest that AF9 may play important roles in leukemogenesis as well as N-terminus of MLL. In another study, Dobson et al 15 reported that knock-in mice expressing N-terminus of MLL fused to bacterial ␤-galactosidase (lacZ) developed leukemia with a longer latency period than MLL-AF9 knock-in mice did. They speculate that oligomerization of the truncated MLL by lacZ domain may be sufficient for a dominant-negative inhibition of the wild-type MLL. Among the known MLL partner proteins, AF10 and AF17 have a leucine zipper protein dimerization motif and this domain is retained in the MLL-AF10 and MLL-AF17 fusion proteins. 16, 17 These results may suggest that a dominant-negative inhibition of wild-type MLL may be sufficient to induce leukemia and partner proteins with transcriptional regulating functions such as AF4 and AF9 facilitate this process. 15 Gene-targeting studies in mice demonstrated that Mll is a positive regulator of the mammalian homeobox (Hox) genes. A posterior shift in the anterior boundaries of the Hox genes expression occurs in the Mll null heterozygotes, while the expression of these genes is abolished completely in the Mll null homozygotes. 18 The HOX homeobox genes are originally identified in Drosophila as responsible genes for homeotic transformations. 19 They encode transcription factors featured by a homeodomain that is a well-conserved DNA binding motif. They are the master regulators of body patterning not only in Drosophila but also in mammals. 20 In mammals 39 different HOX genes are organized into four clusters (HOXA, -B, -C, and -D) and they are located on each different chromosome. 21 Each cluster contains 9-11 genes that are classified into 13 subgroups called 'paralog'. 22 Accumulating evidence indicates that the HOX genes are involved in hematopoiesis as well as in embryonic development. 23, 24 Several members of the HOXA, -B, and -C cluster genes are expressed in human hematopoietic cells and their expression patterns are closely related to a cell lineage and stage of differentiation. 25 Deregulation of the HOX genes profoundly perturbs normal hematopoietic development. 23, 24 Namely, the enforced expression of HOXA10 26 or Hoxa9 in combination with its cofactor Meisl 27 transforms murine hematopoietic cells. Thus, it is conceivable that altering the expression of the HOX genes by the MLL aberration is important in leukemogenesis. However, it is not known whether or not the MLL chimeric proteins regulate the expression of the HOX genes in human leukemia.
In this study, we demonstrated that down-regulation of MLL-AF9 with antisense oligodeoxy-ribonucleotide (ODN) reduced the expression level of the selected HOX genes and induced apoptosis in THP-1 cells. Our results support the gain-of-function feature of MLL-AF9 fusion protein. 
Materials and methods

Leukemia cell lines
Treatment of THP-1 cells with antisense or sense ODN against the MLL-AF9 chimeric transcript
THP-1 is a human monocytic leukemia cell line carrying the t(9;11) chromosomal translocation. Another human leukemia cell line, HL-60, which has no t(9;11), was also used to test the specificity of the ODN treatment. The nucleotide sequence around the breakpoint of the MLL and AF9 genes in THP-1 was obtained from GenBank (accession No. AJ000161), and antisense phosphorothioate ODN complementary to the coding sequence of the MLL-AF9 junction cDNA (antisense MLL-AF9, 5Ј-GGTTGTTCAGACTTT-3Ј) was synthesized. In control experiments, the sense phosphorothioate ODN (sense MLL-AF9, 5Ј-AAAGTCTGAACAACC-3Ј) corresponding to the same region was used. ODN treatments were performed in triplicate by plating 1 × 10 4 cells in 200 l of RPMI1640 medium containing 2% heat-inactivated FCS supplemented with 20 m antisense or sense ODN in wells of a 48-well plate. Control cultures without adding any ODN were also prepared in triplicate. Cells were incubated at 37°C in a 5% CO 2 incubator and the cell viability was determined by a trypan blue dye exclusion method at days 1, 3, and 5.
RT-PCR analysis of the MLL-AF9 chimeric transcript
Total RNA was extracted from 1 × 10 4 or 2 × 10 4 viable cells by guanidium isothiocyanate lysis/ethanol precipitation as described. 31 For reverse transcription, total RNA was resuspended in 10 l of RT solution consisting of 1 × RT buffer (Life Technologies, Rockville, MD, USA), 10 mm dithiothreitol, 0.5 mm dNTPs (Takara, Kyoto, Japan), 25 ng/l oligo(dT) primer (Amersham-Pharmacia Biotech, Buckinghamshire, UK), 0.2 units/l RNase inhibitor (Life Technologies), and 10 units/l SuperScript II reverse transcriptase (Life Technologies). The sample was incubated at 42°C for 1 h, and then heated at 70°C for 10 min. For the detection of the MLL-AF9 chimeric transcripts, 1 l (1/10 volume) of the cDNA solution was mixed with a PCR solution consisting of 1 × Taq buffer (Takara), 5 mm MgCl 2 , 2 m each primer, 1 mm dNTPs, and 0.1 unit/l Taq DNA polymerase (Takara). The sequences of the primers for the MLL-AF9 chimeric transcript were as follows: forward primer: 5Ј-TCCAGGAAGTCAAGCAAGCA-3Ј and reverse primer: 5Ј-TTGTTGCCTGGTCTGGGAT-3Ј. The PCR condition that linearly amplified MLL-AF9 was determined by testing the several conditions on the dilution series of the cDNA generated from 2 × 10 4 THP-1 cells. The optimized PCR condition was as follows: 23 cycles of 94°C for 1 min; 65°C for 1 min; 72°C for 2 min. As an internal control, PCR detection of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcript was performed. The sequences of the primers for the GAPDH transcript were: forward: 5Ј-TGGTATCGTGGAAGGACTCATGAC-3Ј and reverse: 5Ј-ATGCCAGTGAGCTTCCCGTTCAGC-3Ј. The PCR condition that linearly amplified GAPDH was determined as described above. The optimized PCR condition was as follows: 20 cycles of 94°C for 1 min; 60°C for 1 min; 72°C for 2 min. The primers used were located in separated exons to exclude the amplified products derived from contaminated genomic DNA. The 300-bp and 180-bp PCR products of MLL-AF9 and GAPDH, respectively, were subcloned into pGEM-T vector (Promega, Madison, WI, USA), sequenced, and used as probes for Southern blot analysis. Densitometric analysis of the blot was performed by using BAS2000 image analyzing system (Fujix, Tokyo, Japan). All densitometric values were divided by those of GAPDH as an internal control from the same samples, and the resulting data (normalized expression levels) were subjected to statistical analysis. Quantitativity of this method is shown in Figure 1 .
Generation of representative amplified total cDNAs
A quantitative analysis for the HOX gene expression was performed by generating representative amplified total cDNAs with an oligo(dT)-based primer and poly(A)-tailing strategy as previously described. 25, 31 The cDNA generated as described above was ethanol precipitated and resuspended in a poly(A)-tailing solution consisting of 1 × terminal deoxynucleotidyl transferase (TdT) buffer (Life Technologies), 10 mm dATP (Amersham-Pharmacia Biotech), and 1.5 units/l TdT (Life Technologies). The sample was incubated at 37°C for 15 min and then at 70°C for 10 min. For an amplification of total cDNA, 5 l of the poly(A)-tailed cDNA solution was mixed with a PCR amplification solution consisting of 1× Taq buffer, 5 mm MgCl 2 , 0.08 g/l 60-mer oligo-dT primer, 25 1 mm each d(GCT) deoxyribonucleotide (Amersham-Pharmacia Biotech), and 0.1 units/l Taq DNA polymerase. PCR was performed under the following conditions: one cycle of 94°C for 1 min; 37°C for 2 min; 72°C for 10 min followed by 40 cycles of 94°C for 1 min; 55°C for 2 min; 72°C for 10 min. We also
Figure 1
Quantitative analysis of MLL-AF9 expression by RT-PCR. MLL-AF9 and control GAPDH were amplified from various cellular preparations of THP-1 cells expressing MLL-AF9 and K562 cells, which do not express it. PCR products were analyzed by Southern blot. The expression level of MLL-AF9 normalized to GAPDH from each preparation was determined by densitometric analysis, and indicated as a percentage to that of lane 1. prepared control samples using the same procedure without adding reverse transcriptase.
Southern blot analysis of the amplified cDNA
The amplified cDNA mixtures were electrophoresed on a 1% agarose gel, denatured, and then transferred to a nylon membrane (Hybond-N + ; Amersham-Pharmacia Biotech). Homeodomain-free cDNA probes of HOXA2, -A4, -A7, and -A10 were generated from following ESTs (Genome Systems, St Louis, MO, USA); HOXA2: AI692874, HOXA4: T82108, HOXA7: AW629455, and HOXA10: AA213855 (numbers indicated are GenBank accession numbers). Homeodomain- . The values shown indicate the mean expression levels of MLL-AF9 (normalized to GAPDH) relative to those in the sense-treated cells. The error bar indicates a standard error (SE). *Indicates that P value was less than 0.05.
Leukemia
Figure 3
Quantitative analysis of HOX gene expression by representative amplification of cDNA. Expression of HOXA10 and ␤-actin was analyzed by Southern blot in amplified total cDNA generated from various cellular preparations of THP-1 cells expressing HOXA10, and K562 cells which do not express it. The expression level of HOXA10 normalized to ␤-actin from each preparation was determined by densitometric analysis, and indicated as a percentage to that of lane 1. free cDNA probes of HOXA5 and -A9 32 were made by RT-PCR with the following primers: HOXA5: forward primer: 5Ј-AGCTGAAAAGCATGAGCATG-3Ј, and reverse primer: 5Ј-CAAGTAACACAGCTTGCTTC-3Ј, HOXA9: forward primer: 5Ј-CTGTTGATGGTAGGCTGTAT-3Ј, and reverse primer: 5Ј-AGGTGGAGAAAATGATGAAT-3Ј. Human ␤-actin cDNA probe (Clontech, Palo Alto, CA, USA) was used for an internal control. These cDNA fragments were labeled with 32 P-dCTP by using a MegaPrime DNA labeling kit (Amersham-Pharmacia Biotech) according to the manufacturer's direction. Blots were hybridized with the radiolabeled probes at 60°C overnight in 4.4 × SSC (NaCl 0.3 m, Na 3 C 6 H 5 O 7 0.03 m, pH 7), 7.5% formamide, 0.75% SDS, 1.5 mm EDTA, 0.75% skim milk, 370 g/ml salmon sperm DNA, and 7.5% dextran sulfate. After hybridization, blots were washed in 0.3 × SSC, 0.1% SDS at 60°C for 30 min twice. Densitometric analysis was performed as described above with the normalization against ␤-actin as an internal control.
Apoptosis detection of ODN-treated THP-1 cells
THP-1 and HL-60 cells (3 × 10 4 cells) cultured with the sense or antisense ODN were washed with phosphate-buffered saline (PBS) and suspended in a binding buffer (Immunotech, Marseille, France) at 1 × 10 5 cells/ml. Cells were incubated with annexin V conjugated with fluorescence isothiocyanate (FITC) (Immunotech) and propidium iodide (PI) according to the manufacturer's direction, and immediately analyzed on a flow cytometer (Epics Elite; Beckman Coulter, Marseille, France). Cells in control cultures without adding any ODN were also analyzed by the same method. For a further assessment of apoptosis, we stained the ODN-treated cells with Hoechst 33258. Cells were fixed in a 1% paraformaldehyde solution, washed with PBS, and incubated with 0.2 mm Hoechst 33258. The stained cells were observed under a fluorescence microscope (Zeiss, Oberkochen, Germany), and the apoptotic changes of nuclei were assessed.
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Statistical analysis
The expression levels of the MLL-AF9 and the HOX genes normalized to those of the internal controls (GAPDH and ␤-actin, respectively) were compared between the antisense-treated cells and the control sense-treated cells by Wilcoxon signedrank test. Statistical significance was assigned when the probability that there was no difference between two variables was Ͻ0.05. Figure 1 . To test it, mixtures of various numbers of THP-1 cells and K562 cells, which has no t(9;11), were made. When the RT-PCR product of MLL-AF9 and GAPDH from each cellular preparation was analyzed by Southern blot, the signal intensity of MLL-AF9 normalized to that of GAPDH is linearly related to the number of THP-1 cells (Figure 1 ). After 3-day culture, 1 × 10 4 viable THP-1 cells were harvested and the expression of MLL-AF9 was analyzed by using this method. Representative example is shown in Figure 2a . The expression levels of MLL-AF9 normalized to those of GAPDH were compared between the sense and antisense ODNtreated cells in independent experiments (n = 7). As shown in Figure 2b To analyze the expression of HOX genes in small numbers of ODN-treated cells, we employed the previously described method for generating PCR-amplified representative total cDNA. 25, 31 The quantitative detection of HOX gene expression by this method is shown in Figure 3 . To test it, mixtures of various numbers of THP-1 cells, which express HOXA10, and K562 cells, which do not express it, were made. When the amplified cDNA from each cellular preparation was analyzed by Southern blot with HOXA10 and ␤-actin probes, the signal intensity of HOXA10 normalized to that of ␤-actin is linearly related to the number of THP-1 cells (Figure 3) .
Results
Effects of the MLL-AF9 antisense ODN treatment on the HOX gene expression
After 3-day culture, 1 × 10 4 viable THP-1 cells were harvested and the amplified cDNAs were generated. Based on the previous data of the HOX gene expression profile in THP-1, 33 the expression of the HOXA2, -A4, -A5, -A7, -A9, and -A10 genes was examined by Southern blot with the specific probes for each HOX gene. A representative result is shown in Figure 4a . The expression levels of these HOX genes normalized to those of ␤-actin were compared between the sense and antisense ODN-treated cells in independent experiments (n = 7). The densitometric analysis of the blots obtained from the independent cultures revealed that the expression levels of the HOXA7 and -A10 genes were significantly decreased in the antisense ODN-treated cells as compared to those in the sense ODN-treated cells (P Ͻ0.05 for both HOXA7 and -A10) (Figure 4b) . The expression levels of these genes in the sense ODN-treated cells were not significantly different from those in the cells cultured without ODN (data not shown). In contrast to HOXA7 and -A10, when the same analysis was performed on the HOXA2, -A4, -A5 and -A9 genes, the expression levels of these genes in the antisense ODN-treated cells were not significantly changed from those in the sense ODN-treated cells (Figure 4b) . To test the specificity of the effect of this antisense ODN on the HOX gene expression in THP-1 cells, HL-60 cells were cultured with the same ODN (n = 6). The expression levels of the HOXA7 and -A10 genes in the antisense ODN-treated HL-60 cells were not significantly different from those in the cells treated with the sense ODN (data not shown). These results suggest that MLL-AF9 positively regulates the expression of the selected HOX genes including HOXA7 and -A10 in THP-1 cells.
Effects of the MLL-AF9 antisense ODN treatment on the growth of THP-1 cells
In a next set of experiments, the effects of the MLL-AF9 antisense ODN on the growth of THP-1 cells were assessed. The numbers of the viable THP-1 cells cultured with the antisense ODN for 3 and 5 days were four-and 10-fold lower than that of the sense ODN-treated cells, respectively (Figure 5a ). The growth of the cells treated with the sense ODN was not different from that of the cells cultured without ODN (Figure 5a) . In contrast to THP-1, such growth inhibition was not observed in HL-60 cells cultured with the same antisense ODN ( Figure  5b ). These results indicate that the growth inhibiting effect of this antisense ODN is specific to the cells expressing MLL-AF9.
Phase-contrast microscopic observation revealed the shrinkage of the antisense ODN-treated cells, which is typically seen in apoptotic cells (data not shown). To detect the early apoptotic change of the cells, the exposition of phosphatidylserine on the cell surface was examined with annexin V-FITC 34 after 3-day culture. As shown in Figure 6a , the number of the annexin V + /PI − cells, which are apoptotic but not necrotic, was two-fold higher in the antisense ODN-treated cells than that in the control. The number of the annexin V + /PI − cells in the sense ODN-treated cells was not increased as compared to that in the cells cultured without ODN (data not shown). And when similar experiments were performed on HL-60 cells, the increase in the number of the apoptotic cells in the antisense ODN-treated cells was not observed (data not shown). For an assessment of a later phase of apoptosis, the nuclear morphological changes that occurred in the ODN-treated cells were observed. Hoechst 33258 staining of the cells cultured for 4 days with the antisense ODN exhibited characteristic morphology to apoptotic cells such as chromatin condensation and nuclear segmentation (Figure 6b ). Such morphological changes were not apparent in the control culture with sense ODN (Figure 6b ). Together, these results suggest that the growth inhibitory effect of the MLL-AF9 antisense ODN is mediated, at least in part, by an induction of apoptosis.
Discussion
Accumulated evidence has indicated that the MLL chimeric proteins induce leukemia. 14 However, their precise roles in leukemogenesis are not well understood. In this article, we demonstrated that down-regulation of the MLL-AF9 transcript Leukemia with the antisense ODN was accompanied by the reduced expression of HOXA7 and -A10 in THP-1 cells while the expression of other HOX genes including HOXA2, -A4, -A5, and -A9 was not affected (Figure 4a, b) . These results suggest that MLL-AF9 positively regulates the expression of the HOXA7 and -A10 genes in THP-1 cells. This is the first evidence demonstrating that the MLL chimeric protein possibly regulates the expression of the HOX genes in human leukemic cells carrying a MLL gene rearrangement. Schreiner et al 35 reported that MLL-ENL strongly transactivates the promoter of the Hoxa7 gene in a cell-type specific manner. This transactivation ability depends on both the methyltransferase homology domain of MLL and the C-terminus of ENL, suggesting a contribution of the ENL portion to this function. 35 Since the Cterminus of ENL shows a significant homology to AF9, 35 it is reasonable to suppose that the AF9 portion contributes to the transactivation of the HOX genes by the MLL-AF9 chimeric protein in a cell-type specific manner. Alternatively, it is also possible to speculate that the apoptotic signal activated by the down-regulation of MLL-AF9 caused the reduced expression of the HOXA7 and -A10 genes in THP-1 cells. This speculation does not seem to be consistent with the previous report showing that the apoptotic signal activated by retinoic acid does not affect the expression of the 5Ј Hox genes in a mouse developing limb. 36 However, further studies will be needed to rule out this possibility. Interestingly, both HOXA7 and -A10 are involved in leukemogenesis. The murine Hoxa7 gene was constitutionally activated by a retroviral insertion in myeloid leukemia that outgrew in BXH-2 mouse together with Hoxa9 and Meis1, a binding partner of Hoxa9. 37 The elevated expression of the HOXA10 gene is frequently found in human acute myeloid leukemia, 32, 38 and its enforced expression in murine hematopoietic cells perturbs the myeloid differentiation and causes leukemia in most mice transplanted with the transduced cells. 26 Thus, the sustained expression of the HOXA7 and -A10 genes by MLL-AF9 may play important roles in determining the transformed phenotype of THP-1 cells.
The antisense ODN against MLL-AF9 induced apoptosis in THP-1 cells (Figure 6a, b) . Akao et al 39 reported that antisense ODN against MLL-ENL induced apoptosis in KOCL33 cells. Taken together, two different MLL fusion proteins, MLL-AF9 and MLL-ENL, prevent apoptosis of leukemic cells. Similar inhibition of apoptosis by oncogenic chimeric proteins has been also observed in other types of leukemias. Namely, targeted down-regulation of BCR-ABL with the antisense ODN induced apoptosis in K562 cells. 40 Likewise, dominant-negative inhibition of the E2A-HLF protein, which is produced by the chromosomal translocation t(17;19)(q22;p13), induced apoptosis in transformed lymphocyte progenitors. 41 In the case of the MLL-AF9 protein, such a disruption of a cell death pathway may be a primary event in leukemogenesis. The knock-in of the chimeric Mll-AF9 gene causes myeloproliferation in mice as early as 6 days after birth, and then leukemia develops after a latency period of 3-7 months. 14, 42 This mouse study suggests that Mll-AF9 conveys a growth advantage on the myeloid progenitors. Our in vitro study supports this observation and MLL-AF9 could provide myeloid progenitors with such a growth advantage through the inhibition of apoptosis. This mechanism may allow the cells to acquire additional genetic hits for full leukemic conversion, otherwise eliminated by p53-dependent or -independent apoptotic mechanisms.
In conclusion, in this article, we have demonstrated that MLL-AF9 regulates the expression of the selected HOX genes and prevents the cells from apoptosis in THP-1 cells. These effects of MLL-AF9 are likely to be important for human leukemogenesis. However, it is possible that they are not the sole mechanisms through which MLL-AF9 transforms cells. Unknown downstream targets of MLL-AF9 other than HOX genes may work in leukemic cells. Identification of such target genes and understanding their biological roles will give us better insights into leukemogenesis induced by MLL-AF9. The antisense ODN against MLL-AF9 will be a useful tool for this end.
